Cureus,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 19, 2024
Type
2
diabetes
mellitus
(T2DM)
is
a
significant
risk
factor
for
cardiovascular
diseases,
prompting
research
into
treatments
that
can
mitigate
this
risk.
Sodium-glucose
cotransporter
(SGLT2)
inhibitors,
particularly
dapagliflozin
and
empagliflozin,
have
shown
promising
benefits
in
T2DM
patients.
This
meta-analysis
aimed
to
directly
compare
the
outcomes
of
these
two
drugs.
To
achieve
this,
we
conducted
comprehensive
literature
search
across
multiple
databases
up
August
5,
2024,
including
both
randomized
controlled
trials
(RCTs)
observational
studies.
The
primary
interest
were
major
adverse
events
(MACE),
atrial
fibrillation
(AF),
mortality,
myocardial
infarction
(MI),
hospitalization
heart
failure
(HF).
Twelve
studies
met
inclusion
criteria
meta-analysis.
pooled
analysis
revealed
several
key
findings.
Notably,
demonstrated
superior
efficacy
preventing
compared
empagliflozin.
However,
no
differences
observed
between
drugs
terms
MACE,
(HHF),
or
infarction.
When
placebo,
empagliflozin
showed
greater
effectiveness
These
results
reinforce
patients
with
T2DM.
comparable
most
suggests
clinicians
flexibility
prescribing
either
SGLT2
inhibitors.
lower
associated
may
be
crucial
treatment
decisions,
especially
history
at
high
fibrillation.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(9), P. 4959 - 4959
Published: May 1, 2024
Some
of
the
most
common
conditions
affecting
people
are
kidney
diseases.
Among
them,
we
distinguish
chronic
disease
and
acute
injury.
Both
entities
pose
serious
health
risks,
so
new
drugs
still
being
sought
to
treat
prevent
them.
In
recent
years,
such
a
role
has
begun
be
assigned
sodium-glucose
cotransporter-2
(SGLT2)
inhibitors.
They
increase
amount
glucose
excreted
in
urine.
For
this
reason,
they
currently
used
as
first-line
drug
type
2
diabetes
mellitus.
Due
their
demonstrated
cardioprotective
effect,
also
heart
failure
treatment.
As
for
renal
effects
SGLT2
inhibitors,
reduce
intraglomerular
pressure
decrease
albuminuria.
This
results
slower
decline
glomelular
filtration
rate
(GFR)
patients
with
disease.
addition,
these
have
anti-inflammatory
antifibrotic
effects.
following
article,
review
evidence
effectiveness
group
nephroprotective
effect.
Further
research
is
needed,
but
meta-analyses
indicate
inhibitors’
efficacy
disease,
especially
one
caused
by
diabetes.
Development
clinical
trials
on
specific
patient
subgroups
will
further
refine
Diabetes Obesity and Metabolism,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 20, 2025
Abstract
Background
Proprotein
convertase
subtilisin/kexin
type
9
(PCSK9)
is
mainly
secreted
by
the
liver,
and
plays
a
crucial
role
in
lipid
metabolism
disorder.
Sodium‐glucose
cotransporter
2
inhibitors
(SGLT2i)
can
regulate
through
various
pathways,
including
reducing
visceral
fat
accumulation,
modulating
serum
lipoprotein
levels
alleviating
hepatic
steatosis.
However,
specific
regulatory
mechanisms
remain
unclear.
Methods
We
built
model
of
glucose
disorder
vivo
vitro,
explored
mechanism
dapagliflozin
regulating
liver
metabolism.
Results
found
that
SGLT2i
significantly
reduced
PCSK9,
total
cholesterol
(TC),
low
density
(LDL‐C)
high‐fat
diet
(HFD)‐fed
mice,
while
also
improving
In
vitro
studies
confirmed
increased
LDL
receptor
(LDLR)
expression
HepG2
cells,
enhancing
their
ability
to
uptake
LDL‐C.
Conclusions
Further
mechanistic
revealed
hepatocyte
nuclear
factor‐1‐alpha
(HNF1α)/PCSK9/LDLR
signalling
pathway
may
be
involved
dapagliflozin's
regulation
homeostasis.
The Russian Archives of Internal Medicine,
Journal Year:
2025,
Volume and Issue:
15(1), P. 17 - 23
Published: Jan. 26, 2025
Atrial
fibrillation
is
one
of
the
most
common
heart
rhythm
disorders
associated
with
an
increased
risk
stroke,
cardiovascular
mortality
and
hospitalizations.
The
development
arrhythmias
influenced
by
a
number
factors,
including
arterial
hypertension,
chronic
failure,
coronary
disease
endocrine
disorders.
New
guidelines
from
European
Society
Cardiology
(2024)
emphasize
importance
managing
factors
to
improve
treatment
efficacy
prognosis
in
patients
atrial
fibrillation.
Sodium-glucose
cotransporter
type
2
inhibitors
(gliflozins),
originally
used
as
hypoglycemic
drugs,
are
now
also
widely
reduce
adverse
events.
However,
use
these
drugs
course
remains
open
question.
In
order
find
answer
this
question,
literature
review
was
conducted,
which
showed
that
sodium-glucose
can
theoretically
have
antiarrhythmic
effect
realized
through
several
mechanisms.
Analysis
scientific
data
suggests
cases,
reduces
first-time
fibrillation,
has
positive
on
arrhythmia
its
recurrence
after
ablation.
At
same
time,
it
not
clear
end
whether
discussed
issues
class-effect
or
belonging
gliflozin
group
different
efficacy.
mentioned
necessitate
further
prospective
studies
confirm
sodiumglucose
inhibitors.
Clinical Research in Cardiology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 18, 2025
Abstract
Aims
A
minority
of
patients
with
heart
failure
(HF)
are
prescribed
the
maximal
dose
angiotensin
receptor–neprilysin
inhibitor
sacubitril/valsartan.
We
investigated
effectiveness
submaximal
doses
sacubitril/valsartan
in
a
real-world
cohort.
Methods
and
results
Patients
HF
reduced
ejection
fraction
for
≥
180
days
between
2016
2020
were
included
from
nationwide
database,
categorized
into
tertiles
based
on
average
daily
dosage.
Baseline
characteristics
balanced
using
inverse
probability
treatment
weighting
propensity
scores.
The
primary
outcome
was
composite
hospitalization
all-cause
mortality.
study
3,953
(age
62.6
±
12.4
years,
73.0%
men).
lower
older,
more
likely
to
be
women,
had
comorbidities,
blood
pressure,
kidney
function,
body
mass
index;
however,
baseline
well
across
groups
after
weighting.
During
mean
follow-up
2.0
0.7
there
808
events
(20.4%).
risk
middle
(HR
0.93,
95%
CI
0.78–1.10)
highest
dosage
0.88,
0.74–1.06)
did
not
significantly
differ
compared
lowest
tertile
(
p
-value
=
0.384).
Regarding
individual
outcomes,
no
significant
difference
hospitalization;
trend
toward
mortality
higher
0.047).
Conclusions
No
observed
different
groups.
This
suggests
that
benefits
may
necessarily
dose-dependent.
Graphical
Clinical
according
their
clinical
outcomes.
women
unfavourable
characteristics.
However,
weighting,
Kaplan–Meier
curves
revealed
differences
regard
hospitalization,
mortality,
combination
these.
Journal of Population Therapeutics and Clinical Pharmacology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 1, 2024
Background:
Dapaglifozin,
a
popular
SGLT
2
inhibitor
is
frequently
used
as
single
or
add
on
therapy
in
type
diabetes
mellitus.
With
its
efficacy
established
through
extensive
clinical
trials,
our
study
aims
to
collect
preliminary
safety
data
dapaglifozin
active
surveillance.
Material
and
Methods:
The
profile
of
was
evaluated
100
patients
aged
>
18
years
either
mono
treatment
for
duration
weeks.
collected
CRF
after
obtaining
consent
4
months
from
April
2022-
July
2022
at
tertiary
care
hospital.
primary
outcome
the
proportion
frequency
AEs,
causality
severity
assessment
AEs.
Secondary
delineated
association
between
sociodemographic
characteristics
with
data.
Result:
On
analysis
patients,
mean
age
57.65
+
12.23
male
preponderance
(57%)
average
BMI
–
27.75
2.42.
About
39%
adverse
events
were
reported,
which
most
common
AEs
increased
fatiguability
(28.2%)(unexpected),
hypoglycemia
(17.9%),
dapa
specific
such
genital
tract
infections
(12.8%)
UTI
(12.8%),
gastro
intestinal
(~10-17%)
backpain-
9.09%.
93%
therapy,
higher
dose(10mg)
administration
(218.7
days)
significantly
associated
events.
Conclusion:
Widespread
application
among
diabetics/nondiabetics
have
been
need
vigilance
real
life
here
contribute
global
incidence
watchlist.
Рецепт,
Journal Year:
2024,
Volume and Issue:
27(2), P. 214 - 231
Published: April 29, 2024
Ингибиторы
натриевого
котранспортера
глюкозы
2
(ИНКТГ2)
широко
используются
в
лечении
сахарного
диабета
2-го
типа
(СД2).
На
примере
ИНКТГ2
дапаглифлозина
продемонстрированы
дополнительные
преимущества
препарата,
включающие
наряду
с
улучшением
компенсации
СД2
без
риска
гипогликемических
эпизодов
снижение
кардиоваскулярного
риска,
вероятности
развития
и
ухудшения
течения
сердечной
недостаточности,
артериального
давления,
уменьшение
фибрилляции
предсердий,
ренопротективные
эффекты
c
минимизацией
анемии,
влияние
на
неалкогольную
жировую
болезнь
печени,
уровня
мочевой
кислоты
др.
Перечисленные
результируются
потенциальное
увеличение
продолжительности
жизни.
Приведенные
факты
определяют
расширение
показаний
для
использования
представителя
класса
–
дапаглифлозина.
Sodium
glucose
cotransporter
inhibitors
(SGLT2
I)
are
widely
used
in
the
type
diabetes
mellitus
(DM2)
treatment.
Using
example
of
SGLT2
I
dapagliflozin,
additional
benefits
drug
have
been
demonstrated,
including,
along
with
improved
compensation
for
DM2
without
hypoglycemic
episodes
risks,
a
decrease
cardiovascular
risk,
likelihood
developing
and
worsening
course
heart
failure,
blood
pressure,
risk
atrial
fibrillation,
renoprotective
effects
minimizing
anemia,
influence
on
non-alcoholic
fatty
liver
disease,
uric
acid
levels
others.
These
result
potential
increase
life
expectancy.
facts
determine
expansion
indications
application
representative
class
dapagliflozin.
